Dr. Reddy’s, Leiner Partnership Focusing On Switches
This article was originally published in The Tan Sheet
Executive Summary
Dr. Reddy's Laboratories and Leiner Health Products are actively looking at potential Rx-to-OTC switch projects as they build on their partnership
You may also be interested in...
Claritin-D Litigation Settlement Reached Between Schering, Andrx
Litigation related to Impax Laboratories' generic version of Schering-Plough's Claritin-D OTC allergy drug is the last pending patent dispute involving the D formulation following a settlement with Andrx
Dr. Reddy’s Stakes Claim In U.S. OTC Market With Leiner Deal
Dr. Reddy's Laboratories' foothold in the U.S. OTC drug market appears ready for expansion after the firm signed an exclusive 15-year OTC product development and marketing agreement with Leiner Health Products
Leiner
Private labeler to begin shipping generic famotidine 10 mg, marketed under ANDA approval granted to Dr. Reddy's Labs, by Oct. 1. Dr. Reddy's ANDA 75-758 for J&J/Merck Pepcid AC equivalent received FDA clearance Aug. 17; Leiner currently markets generic ranitidine 75 mg (Pfizer/Warner-Lambert's Zantac 75) for Dr. Reddy's. Leiner joins Perrigo (marketing under a license from Teva) and Ivax in OTC generic famotidine market (1"The Tan Sheet" Aug. 6, In Brief)